Cargando…

The ocular distribution of (14)C-labeled bromfenac ophthalmic solution 0.07% in a rabbit model

PURPOSE: To evaluate the ocular distribution of an advanced formulation of bromfenac ophthalmic solution. Two studies were conducted in rabbits: 1) a 12-hour parallel-group study comparing the ocular distribution of (14)C-bromfenac ophthalmic solution 0.07%, pH 7.8 with that of (14)C-bromfenac ophth...

Descripción completa

Detalles Bibliográficos
Autores principales:	Baklayan, George A, Muñoz, Mauricio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2014
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4160328/ https://www.ncbi.nlm.nih.gov/pubmed/25228788 http://dx.doi.org/10.2147/OPTH.S66638

Ejemplares similares

In Vivo Pharmacokinetics of Bromfenac Ophthalmic Solution 0.075%, Bromfenac Ophthalmic Solution 0.07%, and Nepafenac/Amfenac Ophthalmic Suspension 0.3% in Rabbits
por: Sheppard, John D., et al.
Publicado: (2018)

The efficacy of bromfenac ophthalmic solution 0.07% dosed once daily in achieving zero-to-trace anterior chamber cell severity following cataract surgery
por: Silverstein, Steven M, et al.
Publicado: (2014)

Bromfenac Ophthalmic Solution 0.07% Versus Nepafenac Ophthalmic Suspension 0.3% for Post-Cataract Surgery Inflammation: A Pilot Study of Identical Dosing Regimens with Pre-Surgical “Pulse” Dose
por: Silverstein, Steven M.
Publicado: (2019)

Comparison of Once-Daily Bromfenac 0.07% Versus Once-Daily Nepafenac 0.3% in Patients Undergoing Phacoemulsification
por: Toyos, Melissa M.
Publicado: (2019)

Management of ocular inflammation and pain following cataract surgery: focus on bromfenac ophthalmic solution
por: Cho, Hyung, et al.
Publicado: (2009)

Bromfenac ophthalmic solution for the treatment of postoperative ocular pain and inflammation: safety, efficacy, and patient adherence
por: Rajpal, Rajesh K, et al.
Publicado: (2014)

Evaluation of analgesic efficacy of bromfenac sodium ophthalmic solution 0.09% versus ketorolac tromethamine ophthalmic solution 0.5% following LASEK or Epi-LASIK
por: Wang, Xiao Jing, et al.
Publicado: (2011)

Fe(0.79)Si(0.07)B(0.14) metallic glass gaskets for high-pressure research beyond 1 Mbar
por: Dong, Weiwei, et al.
Publicado: (2022)

Effects of Intercritical Annealing Temperature on Mechanical Properties of Fe-7.9Mn-0.14Si-0.05Al-0.07C Steel
por: Zhao, Xianming, et al.
Publicado: (2014)

Effect of Solution pH on Distribution of Ophthalmically Administered Brimonidine in Posterior Ocular Tissues in Pigmented Rabbits
por: Shinno, Keisuke, et al.
Publicado: (2019)

Tuning Magnetic Entropy Change and Relative Cooling Power in La(0.7)Ca(0.23)Sr(0.07)MnO(3) Electrospun Nanofibers
por: Burrola Gándara, Luis Andrés, et al.
Publicado: (2020)

Calculation of absorbed dose at 0.07-, 3.0- and 10.0-mm- depths in a slab phantom for monoenergetic electrons
por: Hirayama, H
Publicado: (1993)

An application of (4YSZ)(0.93)(Fe(2)O(3))(0.07) in limiting current oxygen sensor
por: Wang, Xiangnan, et al.
Publicado: (2019)

Ocular pharmacokinetics of bimatoprost formulated in DuraSite compared to bimatoprost 0.03% ophthalmic solution in pigmented rabbit eyes
por: Shafiee, Afshin, et al.
Publicado: (2013)

Personal dose equivalent H(p)(0.07) during (68)Ga-DOTA-TATE production procedures
por: Wrzesień, M., et al.
Publicado: (2023)

Bromfenac 0.09% for the Treatment of Macular Edema Secondary to Noninfectious Uveitis
por: Saade, Joanna S., et al.
Publicado: (2021)

Using Monte Carlo methods for H(p)(0.07) values assessment during the handling of (18)F-FDG
por: Albiniak, Łukasz, et al.
Publicado: (2020)

Efficacy and safety of bromfenac 0.09% and sodium hyaluronate 0.4% combination therapy, versus placebo in patients with pterygium I–III for clinical signs on ocular inflammation
por: Chávez-Mondragón, Eduardo, et al.
Publicado: (2019)

Post-Marketing Surveillance of Levofloxacin 0.5% Ophthalmic Solution for External Ocular Infections
por: Kanda, Yoshiko, et al.
Publicado: (2012)

Tuning of the Structure and Magnetocaloric Effect of Mn(1−x)Zr(x)CoGe Alloys (Where x = 0.03, 0.05, 0.07, and 0.1)
por: Kutynia, Karolina, et al.
Publicado: (2021)

Chondroitin sulfate-chitosan nanoparticles for ocular delivery of bromfenac sodium: Improved permeation, retention, and penetration
por: Abdullah, Tara Abdulrahman, et al.
Publicado: (2016)

Comparative study of the ocular efficacy and safety of diclofenac sodium (0.1%) ophthalmic solution with that of ketorolac tromethamine (0.5%) ophthalmic solution in patients with acute seasonal allergic conjunctivitis
por: Dehar, Navdeep, et al.
Publicado: (2012)

Combination of Aflibercept and Bromfenac Therapy in Age-Related Macular Degeneration: A Pilot Study Aflibercept and Bromfenac in AMD
por: Wyględowska-Promieńska, Dorota, et al.
Publicado: (2015)

New superconductor Li(x)Fe(1+δ)Se (x ≤ 0.07, T(c) up to 44 K) by an electrochemical route
por: Alekseeva, Anastasia M., et al.
Publicado: (2016)

A randomized double-masked study to compare the ocular safety, tolerability, and efficacy of bromfenac 0.075% compared with vehicle in cataract surgery subjects
por: Hosseini, Kamran, et al.
Publicado: (2016)

Brimonidine Ophthalmic Solution 0.025% for Reduction of Ocular Redness: A Randomized Clinical Trial
por: McLaurin, Eugene, et al.
Publicado: (2018)

Ocular pharmacokinetics and tolerability of bimatoprost ophthalmic solutions administered once or twice daily in rabbits, and clinical dosing implications
por: Shen, Jie, et al.
Publicado: (2017)

Thermal activation energy of 3D vortex matter in NaFe(1−x)Co(x)As (x = 0.01, 0.03 and 0.07) single crystals
por: Choi, W. J., et al.
Publicado: (2017)

Update on twice-daily bromfenac sodium sesquihydrate to treat postoperative ocular inflammation following cataract extraction
por: Carreño, Ester, et al.
Publicado: (2012)

Bimatoprost 0.03% preservative-free ophthalmic solution versus bimatoprost 0.03% ophthalmic solution (Lumigan) for glaucoma or ocular hypertension: a 12-week, randomised, double-masked trial
por: Day, Douglas G, et al.
Publicado: (2013)

Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension
por: Hoy, Sheridan M.
Publicado: (2018)

Ocular pharmacokinetics and tolerability of bimatoprost ophthalmic solutions administered once or twice daily in rabbits, and clinical dosing implications [Corrigendum]
Publicado: (2018)

Bimatoprost 0.03%/timolol 0.5% preservative-free ophthalmic solution versus bimatoprost 0.03%/timolol 0.5% ophthalmic solution (Ganfort) for glaucoma or ocular hypertension: a 12-week randomised controlled trial
por: Goldberg, Ivan, et al.
Publicado: (2014)

Effect of 0.1% Bromfenac for Preventing Macular Edema after Cataract Surgery in Patients with Diabetes
por: Song, Seok Hyeon, et al.
Publicado: (2020)

Dielectric, Piezoelectric, and Vibration Properties of the LiF-Doped (Ba(0.95)Ca(0.05))(Ti(0.93)Sn(0.07))O(3) Lead-Free Piezoceramic Sheets
por: Cheng, Chien-Min, et al.
Publicado: (2018)

The Effect of Substitution of Mn by Pd on the Structure and Thermomagnetic Properties of the Mn(1−x)Pd(x)CoGe Alloys (Where x = 0.03, 0.05, 0.07 and 0.1)
por: Kutynia, Karolina, et al.
Publicado: (2023)

Use of topical bromfenac for treating ocular pain and inflammation beyond cataract surgery: a review of published studies
por: Schechter, Barry A
Publicado: (2019)

A Fully Integrated, Power-Efficient, 0.07–2.08 mA, High-Voltage Neural Stimulator in a Standard CMOS Process
por: Palomeque-Mangut, David, et al.
Publicado: (2022)

Bromfenac 0.09% bioavailability in aqueous humor, prophylactic effect on cystoid macular edema, and clinical signs of ocular inflammation after phacoemulsification in a Mexican population
por: Palacio, Claudia, et al.
Publicado: (2016)

The Effects of Two Non-Steroidal Anti-Inflammatory Drugs, Bromfenac 0.1% and Ketorolac 0.45%, on Cataract Surgery
por: Jung, Ji Won, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_mpdbjaj63bos8mv3ifp0cib359